meridian BIOSCIENCE™

FY2020 Q2 Results
May 8, 2020

Forward Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “continues”, “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “signals”, “should”, “can” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings, sales, product demand, revenue, and the impact of COVID-19 on our business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:

Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process (including the currently ongoing study and other FDA actions regarding the Company’s LeadCare products). The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. Meridian also is subject to risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as the coronavirus disease COVID-19. In addition to the factors described in this paragraph, please also refer to additional factors identified from time to time in our filings with the Securities and Exchange Commission, including in Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K, which contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.

Non-GAAP Financial Measures

Certain financial measures presented in this presentation, such as operating expenses, operating income, net earnings and diluted earnings per share, excluding as applicable the effects of acquisition-related costs, a change in fair value of contingent consideration obligation, restructuring costs and selected legal costs, are not recognized under generally accepted accounting principles in the United States of America, or U.S. GAAP. Management believes this non-GAAP financial information is useful to an investor in evaluating our performance, as these measures: (i) help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and (ii) are used by management for various purposes, including evaluating performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting. While we believe these financial measures are commonly used by investors to evaluate our performance and that of our competitors, the non-GAAP measures in this presentation may be different from non-GAAP measures used by other companies and should not be considered as an alternative to performance measures derived in accordance with U.S. GAAP.

In addition, the non-GAAP measures presented herein are not based on any comprehensive set of accounting rules or principles. These non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP, and they should not be considered as alternatives to information attributable to Meridian Bioscience, Inc. determined in accordance with U.S. GAAP. See the consolidated financial statements included in our reports filed with the U.S. Securities and Exchange Commission for our U.S. GAAP results. Additionally, for reconciliations of the non-GAAP measures included herein to our closest reported U.S. GAAP measures, refer to the reconciliations included in the press release of Meridian Bioscience, Inc. dated May 8, 2020.

Q2 FY2020 Business Highlights

- Life Science rapidly responds to COVID-19 & record revenue
- YoY quarterly revenue growth for Diagnostics segment
- Curian® analyzer and HpSA® assay receive FDA clearance
- Acquisition of Exalenz Bioscience Ltd. and BreathID® platform

Diagnostics

Life Science

FY2020 Second Quarter Earnings Summary
($000's except Per Share Amounts)

Adjusted (Non-GAAP)	FY2020	FY2019	Change
Revenue	$57,296	$50,248	+14%
Gross Margin %	*60.1%*	*58.4%*	*+1.7 pts*
Operating expenses[1] *Ratio*	$22,380 *39.1%*	$18,115 *36.1%*	+24% *+3.0 pts*
Operating income *Margin %*	$12,074 *21.1%*	$11,223 *22.3%*	+8% *-1.2 pts*
Net earnings EPS	$10,004 $0.23	$8,159 $0.19	+23% +21%

GAAP	FY2020	FY2019	Change
Operating expenses	$22,663	$19,503	+16%
Operating income Margin %	$11,791 20.6%	$9,835 19.6%	+20% +1.0 pts
Net earnings EPS	$9,359 $0.22	$7,094 $0.17	+32% +29%

Highlights

- Both Diagnostics and Life Science delivered revenue growth above expectations

  -Diagnostics +4%
  -Life Science +33%

- 2020 Gross margin reflects positive effects of mix of Life Science products (molecular vs. immuno) and larger-than-normal batch sizes for RNA master mixes in response to COVID-19 pandemic

- 2020 Operating expenses reflect additional investment in Diagnostics new product development; purchase accounting amortization for the GenePOC acquisition; and additional investment in incentive compensation

1) Includes Corporate segment expenses of $2.2M and $1.6M in FY2020 and FY2019, respectively.

FY2020 Second Quarter
Operating Segment Highlights ($000's)

Diagnostics (Adjusted Non-GAAP)	FY2020	FY2019	Change
Revenue	$34,942	$33,500	+4%
Operating income *Margin %*	$3,337 *9.6%*	$7,436 *22.2%*	-55% *-12.6 pts*

Diagnostics revenue by:			
Technology:			
Molecular assays	$7,238	$7,084	+2%
Immunoassays & blood chemistry	27,704	26,416	+5%
Disease State:			
GI (Gastrointestinal)	$14,014	$16,177	-13%
RI (Respiratory Illnesses)	10,863	7,553	+44%
Blood Chemistry (Lead)	4,329	4,330	- %
Other	5,736	5,440	+5%

Product / Customer Highlights:

- RI volume growth strong in Flu, GAS and Mycoplasma
- GI affected by volume declines in most major assays, as well as Hp contract price changes
- Blood Chemistry experienced lower order patterns in March (non-critical care assay)

Life Science (Adjusted Non-GAAP)	FY2020	FY2019	Change
Revenue	$22,354	$16,748	+33%
Operating income *Margin %*	$10,921 *48.9%*	$5,386 *32.2%*	+103% *+16.7 pts*

Life Science revenue by:			
Technology:			
Molecular reagents	$11,534	$5,390	+114%
Immunological reagents	10,820	11,358	-5%
Region:			
Americas	$4,612	$5,454	-15%
EMEA	9,946	7,852	+27%
ROW	7,796	3,442	+126%
China (included in ROW)	5,312	1,328	+300%

Product / Customer Highlights:

- Record-level molecular reagent shipments ($5.6M related to COVID-19)
- Shipments to industrial customers increased ~40%

FY2020 Fiscal Year Guidance

Prior Guidance

Meridian Bioscience

Consolidated net revenues: Flat to Down 3%
Adjusted operating margin: 9% to 10%
Tax rate: 23.5% to 24.5%
Adjusted earnings per share: $0.28 to $0.34
Research and development spend: $27 to $28 Million

Diagnostics

Net revenues: Down 3% to 5%
Adjusted operating margin: Mid-single-digits

Life Science

Net revenues: Up 2% to 6%
Adjusted operating margin: 50 to 100 basis point improvement over 2019

Updated FY2020 Guidance

Meridian Bioscience

Consolidated net revenues: $230 to $236 Million
Adjusted operating margin: 18% to 19%
Adjusted earnings per share: $0.70 to $0.75

Diagnostics

Net revenues: $120 to $122 million

Life Science

Net revenues: $110 to $114 million

COVID-19 Response

COVID-19 Products & Pipeline

DIAGNOSTICS

RI Panel w/ SARS-CoV-2
(In Development)

Rapid
Immunoassay

Molecular | Immunological

LIFE SCIENCE

For Tests to check for
SARS-CoV-2 Virus

Reagent
Master Mixes

For Tests to check for
SARS-CoV-2 Antibodies



Recombinant
Antigens

Molecular | Immunological

meridian BIOSCIENCE
LIFE DISCOVERED. LIFE DIAGNOSED.

Exalenz Bioscience Ltd. Acquisition

Exalenz Strategic Fit and Rationale

Adds multi-configuration BreathID® diagnostics platform

Flexible configurations span the continuum from large reference labs to point-of-care

H. pylori urea breath test compliments stool antigen tests

Strengthens opportunity to convert of *H. pylori* serology testing to Meridian products

FDA-cleared / CE marked assay with customer base

In-market product with immediate revenue and gross profit contribution

Leverage of Meridian commercial infrastructure

Experienced sales and marketing team to drive *H. pylori* market penetration

Established manufacturing with cost reduction initiatives

Capacity to scale production for growth and opportunities to reduce consumable cost

Exalenz Bioscience BreathID® System

High volume

- Automated benchtop system for press and walk away batch testing
- Samples collected in physician office using breath bags sent to centralized location
- Test up to **10** patients at a time
- 100% sensitivity / 97.9% specificity

Independent Labs

Large Hospitals

Mid volume

- Compact automated benchtop system for press-and-walk-away batch testing
- Samples collected in physician office using breath bags sent to centralized location
- Test up to **4** patients at a time
- 100% sensitivity / 97.9% specificity

Medium Hospitals

Small Hospitals

Low volume

- POC test system using a continuous flow of patient breath through a nasal canula
- Samples in the physician office with results after 15 minutes
- Test **1** patient at a time
- 100% sensitivity / 99.2% specificity

Physician Office Labs

meridian BIOSCIENCE
LIFE DISCOVERED. LIFE DIAGNOSED.

Specimen Collection Workflow

(for BreathID Lab and BreathID Smart)

BASELINE

breath sample collected by patient blowing into **BLUE** breath bag

Patient drinks ^{13}C Urea labeled solution and waits

20 minutes

POST-INGESTION

breath sample collected by patient blowing into **GRAY** breath bag

Breath bags are placed on analyzer and results are read within

2 minutes

meridian BIOSCIENCE
LIFE DISCOVERED. LIFE DIAGNOSED.

BreathID® Assay Workflow

Start ●●●●●●●●●●●●●● In 2 minutes ●●●●●●●●●●●▶ **Results**

Step 1

Scan bag barcode

Step 2

Batch set up

Step 3

Press start

meridian BIOSCIENCE
LIFE DISCOVERED. LIFE DIAGNOSED.

Historical Financial Overview



Source: Exalenz Bioscience Ltd. 2019 consolidated financial statements prepared in accordance with IFRS; accounting policies under IFRS may differ from Meridian's accounting under U.S. GAAP.

Curian® Analyzer

The Curian® Advantage

Fluorescent analyzer
Improved performance with no subjectivity

Intuitive user interface
Intuitive, fast, and easy-to-use improves productivity

Simple sample prep
Clean, comfortable handling of samples

Easy, standardized workflow
Implement & train only once

Curian® Present and Future

Current Menu

- HpSA® FDA CLEARED CE

Launched May 1st, 2020

Future Assay Roadmap

- *C. difficile* GDH/Toxin
- Campy
- EHEC

meridian BIOSCIENCE LIFE DISCOVERED. LIFE DIAGNOSED.

Curian® Assay Workflow
Standardized Simplified Workflow

Step 1

Discharge sample & vortex



Step 2

Add sample to device card

Step 3

Place card into analyzer and start

Curian Video

meridian BIOSCIENCE
LIFE DISCOVERED. LIFE DIAGNOSED.

Contact: mbi@meridianbioscience.com